These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

656 related articles for article (PubMed ID: 23588942)

  • 1. The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus.
    Akhavan PS; Su J; Lou W; Gladman DD; Urowitz MB; Fortin PR
    J Rheumatol; 2013 Jun; 40(6):831-41. PubMed ID: 23588942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A descriptive study of the factors associated with damage in Malaysian patients with lupus nephritis.
    Shaharir SS; Ghafor AH; Said MS; Kong NC
    Lupus; 2014 Apr; 23(4):436-42. PubMed ID: 24399814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A cross-sectional study of hydroxychloroquine concentrations and effects in people with systemic lupus erythematosus.
    Carmichael SJ; Day RO; Tett SE
    Intern Med J; 2013 May; 43(5):547-53. PubMed ID: 23425382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydroxychloroquine-induced pigmentation in patients with systemic lupus erythematosus: a case-control study.
    Jallouli M; Francès C; Piette JC; Huong du LT; Moguelet P; Factor C; Zahr N; Miyara M; Saadoun D; Mathian A; Haroche J; De Gennes C; Leroux G; Chapelon C; Wechsler B; Cacoub P; Amoura Z; Costedoat-Chalumeau N;
    JAMA Dermatol; 2013 Aug; 149(8):935-40. PubMed ID: 23824340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discontinuation of antimalarial drugs in systemic lupus erythematosus.
    Wang C; Fortin PR; Li Y; Panaritis T; Gans M; Esdaile JM
    J Rheumatol; 1999 Apr; 26(4):808-15. PubMed ID: 10229401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydroxychloroquine reduces risk of incident diabetes mellitus in lupus patients in a dose-dependent manner: a population-based cohort study.
    Chen YM; Lin CH; Lan TH; Chen HH; Chang SN; Chen YH; Wang JS; Hung WT; Lan JL; Chen DY
    Rheumatology (Oxford); 2015 Jul; 54(7):1244-9. PubMed ID: 25587177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus.
    Costedoat-Chalumeau N; Amoura Z; Hulot JS; Hammoud HA; Aymard G; Cacoub P; Francès C; Wechsler B; Huong du LT; Ghillani P; Musset L; Lechat P; Piette JC
    Arthritis Rheum; 2006 Oct; 54(10):3284-90. PubMed ID: 17009263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical impact of hydroxychloroquine dose adjustment according to the American Academy of Ophthalmology guidelines in systemic lupus erythematosus.
    Vázquez-Otero I; Medina-Cintrón N; Arroyo-Ávila M; González-Sepúlveda L; Vilá LM
    Lupus Sci Med; 2020 May; 7(1):. PubMed ID: 32434863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longterm Hydroxychloroquine Therapy and Low-dose Aspirin May Have an Additive Effectiveness in the Primary Prevention of Cardiovascular Events in Patients with Systemic Lupus Erythematosus.
    Fasano S; Pierro L; Pantano I; Iudici M; Valentini G
    J Rheumatol; 2017 Jul; 44(7):1032-1038. PubMed ID: 28507183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L).
    Alarcón GS; McGwin G; Bertoli AM; Fessler BJ; Calvo-Alén J; Bastian HM; Vilá LM; Reveille JD;
    Ann Rheum Dis; 2007 Sep; 66(9):1168-72. PubMed ID: 17389655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus.
    Jung H; Bobba R; Su J; Shariati-Sarabi Z; Gladman DD; Urowitz M; Lou W; Fortin PR
    Arthritis Rheum; 2010 Mar; 62(3):863-8. PubMed ID: 20131232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Clinical Outcomes in a Cohort of Adults With Childhood-Onset Systemic Lupus Erythematosus.
    Groot N; Shaikhani D; Teng YKO; de Leeuw K; Bijl M; Dolhain RJEM; Zirkzee E; Fritsch-Stork R; Bultink IEM; Kamphuis S
    Arthritis Rheumatol; 2019 Feb; 71(2):290-301. PubMed ID: 30152151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Review of the literature.
    Costedoat-Chalumeau N; Amoura Z; Huong DL; Lechat P; Piette JC
    Autoimmun Rev; 2005 Feb; 4(2):111-5. PubMed ID: 15722258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study).
    Costedoat-Chalumeau N; Galicier L; Aumaître O; Francès C; Le Guern V; Lioté F; Smail A; Limal N; Perard L; Desmurs-Clavel H; Boutin du LT; Asli B; Kahn JE; Pourrat J; Sailler L; Ackermann F; Papo T; Sacré K; Fain O; Stirnemann J; Cacoub P; Jallouli M; Leroux G; Cohen-Bittan J; Tanguy ML; Hulot JS; Lechat P; Musset L; Amoura Z; Piette JC;
    Ann Rheum Dis; 2013 Nov; 72(11):1786-92. PubMed ID: 23144449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between hydroxychloroquine levels and disease activity in a predominantly Hispanic systemic lupus erythematosus cohort.
    Geraldino-Pardilla L; Perel-Winkler A; Miceli J; Neville K; Danias G; Nguyen S; Dervieux T; Kapoor T; Giles J; Askanase A
    Lupus; 2019 Jun; 28(7):862-867. PubMed ID: 31122136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cumulative dose of hydroxychloroquine is associated with a decrease of resting heart rate in patients with systemic lupus erythematosus: a pilot study.
    Cairoli E; Danese N; Teliz M; Bruzzone MJ; Ferreira J; Rebella M; Cayota A
    Lupus; 2015 Oct; 24(11):1204-9. PubMed ID: 25852050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydroxychloroquine in systemic lupus erythematosus (SLE).
    Ponticelli C; Moroni G
    Expert Opin Drug Saf; 2017 Mar; 16(3):411-419. PubMed ID: 27927040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual.
    Fessler BJ; Alarcón GS; McGwin G; Roseman J; Bastian HM; Friedman AW; Baethge BA; Vilá L; Reveille JD;
    Arthritis Rheum; 2005 May; 52(5):1473-80. PubMed ID: 15880829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal Evaluation of Lipoprotein Variables in Systemic Lupus Erythematosus Reveals Adverse Changes with Disease Activity and Prednisone and More Favorable Profiles with Hydroxychloroquine Therapy.
    Durcan L; Winegar DA; Connelly MA; Otvos JD; Magder LS; Petri M
    J Rheumatol; 2016 Apr; 43(4):745-50. PubMed ID: 26834214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus.
    Costedoat-Chalumeau N; Amoura Z; Hulot JS; Aymard G; Leroux G; Marra D; Lechat P; Piette JC
    Ann Rheum Dis; 2007 Jun; 66(6):821-4. PubMed ID: 17324970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.